Idexx Laboratories (IDXX) | Stock Overview & Key Data
Idexx Laboratories Performance Comparison
Stock Range
Today's Range
Low: $650.78
High: $661.10
on August 15, 2025
52 Week Range
Low: $356.14
High: $688.12
on April 9, 2025
on August 4, 2025
All-Time High: $706.95 on July 26, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$52.1B
EPS
12.04
P/E Ratio (TTM)
54.06
Forward P/E
54.42
P/B Ratio
35.76
PEG Ratio
1.11
Div. Yield
N/A
ROE
64.87%
Beta
1.496
Debt to Equity
84.81
Financial Highlights
Profitability
Gross Margin
62.62%
Operating Margin
33.62%
Profit Margin
24.41%
Returns and Earnings
Return on Assets (TTM)
23.26%
Return on Equity (TTM)
64.87%
EBITDA
$1.4B
Net Income (TTM)
$985.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$49.48
Quarterly Revenue Growth (YoY)
10.60%
Quarterly Earnings Growth (YoY)
44.60%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories IDXX | 52.07B Large-cap | -1.10% | 23.58% | 27.12% | 44.93% | 59.19% | 32.21% | 74.14% | 69.73% |
| Thermo Fisher TMO | 184.66B Large-cap | 6.14% | 16.99% | 20.76% | -6.52% | -6.42% | -19.04% | -16.91% | 14.10% |
| Danaher DHR | 151.04B Large-cap | 5.17% | 9.37% | 10.46% | 3.13% | -8.22% | -21.68% | -18.64% | 14.50% |
| Agilent Technologies A | 33.86B Large-cap | 4.00% | 5.54% | 6.05% | -11.83% | -10.66% | -14.88% | -13.38% | 21.26% |
| Iqvia Holdings IQV | 32.49B Large-cap | 6.24% | 21.19% | 36.07% | -1.07% | -2.07% | -20.26% | -20.05% | 21.27% |
| Mettler-Toledo MTD | 27.03B Large-cap | 4.49% | 12.30% | 14.78% | 3.08% | 7.50% | -7.42% | -1.61% | 36.70% |
Ownership & Short Interest
Insider Ownership
0.68%
Institutional Ownership
97.59%
Shares Short
2M
Short Ratio
4.68
Short % of Shares Outstanding
4.06%
Average 10-Day Volume
983K
Average 90-Day Volume
699K
Idexx Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Idexx Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is IDXX's 52-week high and low?
- In the last 52 weeks, Idexx Laboratories reached a high of $688.12 (on August 4, 2025) and a low of $356.14 (on April 9, 2025).
- What is the market cap and P/E ratio for IDXX?
- Curious about Idexx Laboratories's size and valuation? Its market capitalization stands at 52.07B. When it comes to valuation, the P/E ratio (trailing twelve months) is 54.06, and the forward P/E (looking ahead) is 54.42.
- Does IDXX pay dividends? If so, what's the yield?
- As for dividends, Idexx Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Idexx Laboratories's main competitors or similar companies to consider before investing?
When looking at Idexx Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO184.66B Healthcare Diagnostics & Research -19.04% -16.91% Danaher
DHR151.04B Healthcare Diagnostics & Research -21.68% -18.64% Agilent Technologies
A33.86B Healthcare Diagnostics & Research -14.88% -13.38% Iqvia Holdings
IQV32.49B Healthcare Diagnostics & Research -20.26% -20.05% Mettler-Toledo
MTD27.03B Healthcare Diagnostics & Research -7.42% -1.61% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Idexx Laboratories, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Idexx Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 64.87%, the Debt to Equity ratio from the most recent quarter is 84.81, and its Gross Profit Margin stands at 62.62%.
- What is the recent revenue and earnings growth for IDXX?
- Looking at Idexx Laboratories's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.60%, and quarterly earnings saw a YoY growth of 44.60%.
- How much of IDXX stock is held by insiders and institutions?
- Wondering who owns Idexx Laboratories stock? Company insiders (like executives and directors) hold about 0.68% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.59%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.